Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit
NEW YORK, December 29, 2025, 22:17 ET — Market closed Gilead Sciences (GILD.O) shares were last up 0.15% at $124.91 on Monday, as investors weighed an analyst note that argued new Medicaid drug-pricing rules would have a limited financial impact on the company’s HIV franchise. Investing.com The call matters now because drugmakers and investors are still parsing a Trump administration pricing push that targets Medicaid and aims to bring U.S. medicine prices closer to those in other wealthy countries. Reuters For Gilead, the focus has been on whether “most-favored-nation” pricing — a policy that effectively ties prices to lower international